Literature DB >> 10195073

First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma.

L Blais1, S Suissa, J F Boivin, P Ernst.   

Abstract

BACKGROUND: Early treatment with inhaled corticosteroids appears to improve clinical symptoms in asthma. Whether a first treatment initiated in the year following the recognition of asthma can prevent major outcomes such as admission to hospital has yet to be studied.
METHODS: A case-control study nested within a cohort of 13,563 newly treated asthmatic subjects selected from the databases of Saskatchewan Health (1977-1993) was undertaken to investigate the effectiveness of a first treatment with inhaled corticosteroids in preventing admissions to hospital for asthma. Study subjects were aged between five and 44 years at cohort entry. First time users of inhaled corticosteroids were compared with first time users of theophylline for a maximum of 12 months of treatment. The two treatments under study were further classified into initial and subsequent therapy to minimize selection bias and confounding by indication. Odds ratios associated with hospital admissions for asthma were estimated using conditional logistic regression. Markers of asthma severity, as well as age and sex, were considered as potential confounders.
RESULTS: Three hundred and three patients admitted to hospital with asthma were identified and 2636 matched controls were selected. subjects initially treated with regular inhaled corticosteroids were 40% less likely to be admitted to hospital for asthma than regular users of theophylline (odds ratio 0.6; 95% CI 0.4 to 1.0). The odds ratio decreased to 0.2 (95% CI 0.1 to 0.5) when inhaled corticosteroids and theophylline were given subsequently.
CONCLUSION: The first regular treatment with inhaled corticosteroids initiated in the year following the recognition of asthma can reduce the risk of admission to hospital for asthma by up to 80% compared with regular treatment with theophylline. This is probably due, at least in part, to reducing the likelihood of a worsening in the severity of asthma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10195073      PMCID: PMC1745145          DOI: 10.1136/thx.53.12.1025

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Can postmarketing surveillance help to effect optimal drug therapy?

Authors:  B L Strom; K L Melmon
Journal:  JAMA       Date:  1979-11-30       Impact factor: 56.272

2.  Drug evaluation after marketing.

Authors:  D Slone; S Shapiro; O S Miettinen; W D Finkle; P D Stolley
Journal:  Ann Intern Med       Date:  1979-02       Impact factor: 25.391

3.  Post-marketing studies of drug efficacy: why?

Authors:  B L Strom; K L Melmon; O S Miettinen
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965

4.  Modeling and variable selection in epidemiologic analysis.

Authors:  S Greenland
Journal:  Am J Public Health       Date:  1989-03       Impact factor: 9.308

5.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics.

Authors:  E F Juniper; P A Kline; M A Vanzieleghem; E H Ramsdale; P M O'Byrne; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1990-10

6.  Biased selection of controls for case-control analyses of cohort studies.

Authors:  J H Lubin; M H Gail
Journal:  Biometrics       Date:  1984-03       Impact factor: 2.571

7.  Post-marketing studies of drug efficacy: how?

Authors:  B L Strom; O S Miettinen; K L Melmon
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

8.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.

Authors:  T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

9.  A case-control study of deaths from asthma.

Authors:  H H Rea; R Scragg; R Jackson; R Beaglehole; J Fenwick; D C Sutherland
Journal:  Thorax       Date:  1986-11       Impact factor: 9.139

10.  Direct and indirect costs of asthma in Canada, 1990.

Authors:  M D Krahn; C Berka; P Langlois; A S Detsky
Journal:  CMAJ       Date:  1996-03-15       Impact factor: 8.262

View more
  20 in total

Review 1.  Low dose inhaled corticosteroids and the prevention of death from asthma.

Authors:  J C Kips; R A Pauwels
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma.

Authors:  S Suissa; P Ernst; A Kezouh
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

3.  Patterns of inhaled antiinflammatory medication use in young underserved children with asthma.

Authors:  Arlene M Butz; Mona Tsoukleris; Michele Donithan; Van Doren Hsu; Kim Mudd; Ilene H Zuckerman; Mary E Bollinger
Journal:  Pediatrics       Date:  2006-12       Impact factor: 7.124

Review 4.  Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Step one for asthma treatment: Beta2-agonists or inhaled corticosteroids?

Authors:  A E Redington
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  The impact of guidelines on long-term asthma care: a study of hospitalised patients in Malta.

Authors:  Antonella Tonna; Dorothy J McCaig; Joseph M Cacciottolo
Journal:  Pharm World Sci       Date:  2004-08

7.  Respiratory medications and risk of asthma death.

Authors:  S F Lanes; L A García Rodríguez; C Huerta
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

8.  Development and validation of database indexes of asthma severity and control.

Authors:  Faranak Firoozi; Catherine Lemière; Marie-France Beauchesne; Amélie Forget; Lucie Blais
Journal:  Thorax       Date:  2007-02-07       Impact factor: 9.139

9.  Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations.

Authors:  William M Tierney; J Franklin Roesner; Roopa Seshadri; Michael G Lykens; Michael D Murray; Morris Weinberger
Journal:  J Gen Intern Med       Date:  2004-03       Impact factor: 5.128

Review 10.  Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk?

Authors:  D Oren; I Nulman; M Makhija; S Ito; Gideon Koren
Journal:  Can Fam Physician       Date:  2004-08       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.